APA (7th ed.) Citation

Rodriguez-Berriguete, G., Ranzani, M., Thambiayah, P., Machado, N., Gotorbe, C., Nderitu, D., . . . Higgins, G. S. (2025). 2821 SHLD2-deficient tumours display high sensitivity to DNA polymerase-theta (Polθ) inhibition combined with radiotherapy. Radiotherapy and oncology, 206, S4006-S4007. https://doi.org/10.1016/S0167-8140(25)01312-X

Chicago Style (17th ed.) Citation

Rodriguez-Berriguete, Gonzalo, et al. "2821 SHLD2-deficient Tumours Display High Sensitivity to DNA Polymerase-theta (Polθ) Inhibition Combined with Radiotherapy." Radiotherapy and Oncology 206 (2025): S4006-S4007. https://doi.org/10.1016/S0167-8140(25)01312-X.

MLA (9th ed.) Citation

Rodriguez-Berriguete, Gonzalo, et al. "2821 SHLD2-deficient Tumours Display High Sensitivity to DNA Polymerase-theta (Polθ) Inhibition Combined with Radiotherapy." Radiotherapy and Oncology, vol. 206, 2025, pp. S4006-S4007, https://doi.org/10.1016/S0167-8140(25)01312-X.